Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Oct 24;19(1):383.
doi: 10.1186/s12891-018-2300-7.

A randomized, controlled study to evaluate the efficacy of intra-articular, autologous adipose tissue injections for the treatment of mild-to-moderate knee osteoarthritis compared to hyaluronic acid: a study protocol

Ian A Jones  1 , Melissa Wilson  2 , Ryan Togashi  1 , Bo Han  3 , Austin K Mircheff  4 , C Thomas Vangsness Jr  5
Affiliations
Randomized Controlled Trial

A randomized, controlled study to evaluate the efficacy of intra-articular, autologous adipose tissue injections for the treatment of mild-to-moderate knee osteoarthritis compared to hyaluronic acid: a study protocol

Ian A Jones et al. BMC Musculoskelet Disord. .

Abstract

Background: Osteoarthritis (OA) is a highly debilitating joint disease that causes progressive, irreversible damage to articular cartilage. OA takes a massive toll on society that has grown in recent decades, but no therapy has been shown to halt or reverse the progression of the disease. The critical need for better treatments and increased interest cellular therapies has spawned a new generation of "minimally manipulated" cell treatments. Autologous adipose tissue injections are among the most controversial of these new treatments. Despite a lack of clinical evidence, adipose tissue injections are often marketed as "stem cell" injections with wide-ranging regenerative benefits. The purpose of this study is to estimate the effect size of the treatment by comparing the efficacy of autologous fat to hyaluronic acid (HA). As a secondary aim, we will test for preliminary evidence of efficacy of autologous fat vs. HA.

Methods: This is a prospective, single-center, parallel-group, randomized, controlled trial. Participants (n = 54) will receive either a single intra-articular, ultrasound-guided injection of autologous adipose tissue or a single intra-articular, ultrasound-guided injection of HA (1:1 ratio). Outcome data will be obtained at baseline, week-6 and month-6. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain domain (WOMAC-A) will be used as the primary outcome measure. Secondary clinical outcome measures include WOMAC (full), clinical anchors (pain, function, and stiffness), and the 29-point Patient-Reported Outcomes Measurement Information System (PROMIS®) profile. We will also take synovial fluid samples and assess sway velocity using a force plate, as well as analyze excess/discard adipose tissue to gain a better understanding of how intra-articular adipose tissue injections influence the biochemical environment of the joint.

Discussion: Given the widespread use of intra-articular fat injections in the United States, it is critical that randomized, controlled human studies evaluating efficacy and biological activity be performed. This study is the first step in addressing this unmet need, but it is not without limitations. The most notable limitations of this study are its small size and lack of blinding, which predisposes the study to both investigator and participant bias.

Trial registration: NCT03242707 // HS-17-00365 // Registration Date (First Posted): August 8, 2018.

Keywords: ADSC; Adipose tissue; Fat MSC; Intra-articular injection; Knee; Lipogems; Osteoarthritis; Stem cell.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was granted ethics approval by the University of Southern California Health Science IRB (IRB# HS-17-00365) on 10/9/2017 and USC Institutional Biosafety Committee (BUA-17-00026). All participants provided written informed consent to participate. A copy of informed consent document has been included (Additional file 4).

Consent for publication

N/A.

Competing interests

Ian A Jones has nothing to disclose.

Melissa Wilson has nothing to disclose.

Ryan Togashi has nothing to disclose.

Bo Han has nothing to disclose.

Austin K. Mircheff, has nothing to disclose.

C. Thomas Vangsness, Jr., is a shareholder and board member of CarthroniX.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study design flow chart
See this image and copyright information in PMC

References

    1. Lories RJ, Luyten FP. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol. Nature Publishing Group. 2011;7:43–49. doi: 10.1038/nrrheum.2010.197. - DOI - PubMed
    1. Murphy L, Helmick CG. The impact of osteoarthritis in the United States: a population-health perspective: a population-based review of the fourth most common cause of hospitalization in U.S. adults. Orthop Nurs. 2012;31:85–91. doi: 10.1097/NOR.0b013e31824fcd42. - DOI - PubMed
    1. Ethgen O, Kahler KH, Kong SX, Reginster J-Y, Wolfe F. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol. 2002;29:1147–1155. - PubMed
    1. Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum. Wiley subscription services, Inc., A Wiley Company. 2009;60:3546–3553. - PubMed
    1. Losina E, Paltiel AD, Weinstein AM, Yelin E, Hunter DJ, Chen SP, et al. Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty. Arthritis Care Res. 2015;67:203–215. doi: 10.1002/acr.22412. - DOI - PMC - PubMed

Publication types

Associated data